Preliminary evidence for the phosphodiesterase type-4 inhibitor, roflumilast, in ameliorating cognitive flexibility deficits in patients with schizophrenia.
Nicholas R LivingstonPeter C T HawkinsJames GilleenRong YeLorena ValdearenasSukhi S ShergillMitul A MehtaPublished in: Journal of psychopharmacology (Oxford, England) (2021)
The results suggest roflumilast has dose-dependent cognitive enhancing effects on the ID/ED task in patients with schizophrenia, and provides sufficient support for larger studies to test roflumilast's role in improving cognitive flexibility deficits in this clinical population.